Immune-related Adverse Event with Checkpoint Inhibitors Might Be an Emerging Underlying Disease of Steroid-related Osteonecrosis of the Femoral Head: A Case Report.

INTRODUCTION

Immune checkpoint inhibitors (ICIs) are increasingly being used in the treatment of advanced metastatic and immunogenic cancers. However, these therapies could cause immune-related adverse events (irAEs), which require high-dose glucocorticoid administration.

CASE REPORT

A 52-year-old man with metastatic renal cell carcinoma received ICI therapy. Two weeks later, he suffered from severe irAEs and received glucocorticoid therapy for 13 months. Twenty-one months after the initiation of glucocorticoid administration, he presented to us with bilateral hip pain and was diagnosed with bilateral osteonecrosis of the femoral head (ONFH).

CONCLUSION

IrAEs associated with ICI therapy might be an emerging underlying disease of ONFH.